Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

When it comes to surveillance, PHAC said provincial and territorial public health agencies must report both “confirmed and ...

Experts and health authorities say that while the risk of human infection with the H5N1 strain of avian influenza remains low ...

2:12 H5N1 avian influenza: B.C. reports 1st suspected human case of bird flu Health Canada has authorized three influenza vaccines that could be used if bird flu became a pandemic, the agency says.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.

Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

Human-to-human transmission is very rare, but as cases among animals rise, many experts are worried the virus could develop ...

TORONTO - Health Canada has approved Moderna’s mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older — but it won’t be available until next year, the company ...